VANCOUVER, BC, Canada – September 6, 2016 – Aspect Biosystems Ltd., a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering, today announced the completion of an oversubscribed financing. Aspect’s financing was supported by both institutional and private investors from across the globe. Proceeds from the current financing will accelerate the commercialization of Aspect’s proprietary Lab-on-a-Printer™ bioprinting technology through the Company’s Early Platform Access Program (EPAP) and strategic partnerships.
“Through this financing, Aspect has assembled a very strong group of investors that share our bold vision and provide key support as we take our technology to the next level of commercialization” said Tamer Mohamed, President and Chief Executive Officer of Aspect Biosystems. “This financing is a testament to our cutting-edge technology, proven ability to execute on our strong business strategy, and the ongoing commitment of our new and existing shareholders. We look forward to the next stage in our growth and evolution as an industry leader in the field of 3D bioprinting.”
About Aspect Biosystems Ltd. Aspect Biosystems Ltd. is an award-winning biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. Aspect was founded in 2013, building on over 10 years of biomedical and engineering research at the University of British Columbia. Aspect’s proprietary Lab-on-a-Printer™ platform technology is capable of creating living Human Tissues on Demand™ for broad applications in the life sciences. Aspect Biosystems’ 3D biofabrication technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine.
Tamer Mohamed, President & CEO,
Aspect Biosystems Ltd.